Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).

R. D. Gelber, A. Goldhirsch, C. Hürny, J. Bernhard, R. J. Simes

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Clinical trials of adjuvant therapies usually measure the effectiveness of treatments by comparing disease-free survival or overall survival. These take into consideration only indirectly the quality of life experienced by the patients. We present some approaches that were developed to assess the impact of adjuvant therapy on the quality of life of breast cancer patients, as well as new methods created to compare treatments based on time spent without symptoms and toxicity (TWiST). The integration of these two methods (measuring quality and comparing duration of time) will provide a new tool for evaluating benefits from treatments given in the adjuvant setting.

Original languageEnglish
Pages (from-to)127-135
Number of pages9
JournalJournal of the National Cancer Institute - Monographs
Issue number11
Publication statusPublished - 1992

Fingerprint

Quality of Life
Clinical Trials
Breast Neoplasms
Therapeutics
Disease-Free Survival
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). / Gelber, R. D.; Goldhirsch, A.; Hürny, C.; Bernhard, J.; Simes, R. J.

In: Journal of the National Cancer Institute - Monographs, No. 11, 1992, p. 127-135.

Research output: Contribution to journalArticle

@article{da8478508e184e7699a12a21946803e6,
title = "Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).",
abstract = "Clinical trials of adjuvant therapies usually measure the effectiveness of treatments by comparing disease-free survival or overall survival. These take into consideration only indirectly the quality of life experienced by the patients. We present some approaches that were developed to assess the impact of adjuvant therapy on the quality of life of breast cancer patients, as well as new methods created to compare treatments based on time spent without symptoms and toxicity (TWiST). The integration of these two methods (measuring quality and comparing duration of time) will provide a new tool for evaluating benefits from treatments given in the adjuvant setting.",
author = "Gelber, {R. D.} and A. Goldhirsch and C. H{\"u}rny and J. Bernhard and Simes, {R. J.}",
year = "1992",
language = "English",
pages = "127--135",
journal = "Journal of the National Cancer Institute. Monographs",
issn = "1052-6773",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).

AU - Gelber, R. D.

AU - Goldhirsch, A.

AU - Hürny, C.

AU - Bernhard, J.

AU - Simes, R. J.

PY - 1992

Y1 - 1992

N2 - Clinical trials of adjuvant therapies usually measure the effectiveness of treatments by comparing disease-free survival or overall survival. These take into consideration only indirectly the quality of life experienced by the patients. We present some approaches that were developed to assess the impact of adjuvant therapy on the quality of life of breast cancer patients, as well as new methods created to compare treatments based on time spent without symptoms and toxicity (TWiST). The integration of these two methods (measuring quality and comparing duration of time) will provide a new tool for evaluating benefits from treatments given in the adjuvant setting.

AB - Clinical trials of adjuvant therapies usually measure the effectiveness of treatments by comparing disease-free survival or overall survival. These take into consideration only indirectly the quality of life experienced by the patients. We present some approaches that were developed to assess the impact of adjuvant therapy on the quality of life of breast cancer patients, as well as new methods created to compare treatments based on time spent without symptoms and toxicity (TWiST). The integration of these two methods (measuring quality and comparing duration of time) will provide a new tool for evaluating benefits from treatments given in the adjuvant setting.

UR - http://www.scopus.com/inward/record.url?scp=0026493395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026493395&partnerID=8YFLogxK

M3 - Article

C2 - 1385719

AN - SCOPUS:0026493395

SP - 127

EP - 135

JO - Journal of the National Cancer Institute. Monographs

JF - Journal of the National Cancer Institute. Monographs

SN - 1052-6773

IS - 11

ER -